Targeting T Cell Co-receptors for Cancer Therapy
- PMID: 27192570
- DOI: 10.1016/j.immuni.2016.04.023
Targeting T Cell Co-receptors for Cancer Therapy
Abstract
Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and additional approvals are expected to broaden the clinical scope of immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Eur Urol. 2015. PMID: 25824720 Review.
-
Checkpoint blocking antibodies in cancer immunotherapy.FEBS Lett. 2014 Jan 21;588(2):368-76. doi: 10.1016/j.febslet.2013.10.015. Epub 2013 Oct 23. FEBS Lett. 2014. PMID: 24161671 Review.
-
Part I: Checkpoint inhibitors in cancer therapy.Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051. Immunotherapy. 2016. PMID: 27197535 No abstract available.
-
[Era of cancer immunotherapy has come].Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):164-71. doi: 10.2177/jsci.39.164. Nihon Rinsho Meneki Gakkai Kaishi. 2016. PMID: 27320931 Review. Japanese.
-
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Int Immunol. 2015. PMID: 25323844 Review.
Cited by
-
Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma.Cancers (Basel). 2021 Apr 16;13(8):1922. doi: 10.3390/cancers13081922. Cancers (Basel). 2021. PMID: 33923463 Free PMC article. Review.
-
Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response.Immunity. 2021 Apr 13;54(4):829-844.e5. doi: 10.1016/j.immuni.2021.02.018. Epub 2021 Mar 10. Immunity. 2021. PMID: 33705706 Free PMC article.
-
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination.Sci Rep. 2019 Oct 22;9(1):15099. doi: 10.1038/s41598-019-51537-7. Sci Rep. 2019. PMID: 31641154 Free PMC article.
-
Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma.Front Cell Dev Biol. 2022 Feb 16;10:842220. doi: 10.3389/fcell.2022.842220. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35252205 Free PMC article.
-
Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.J Immunother Cancer. 2019 Dec 11;7(1):346. doi: 10.1186/s40425-019-0812-9. J Immunother Cancer. 2019. PMID: 31829270 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials